RT Journal Article
SR Electronic
T1 754 Phase 1 trial of LYL797, a ROR1-targeted CAR T-cell therapy enhanced with genetic and epigenetic reprogramming, in advanced triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC)
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP A850
OP A850
DO 10.1136/jitc-2023-SITC2023.0754
VO 11
IS Suppl 1
A1 Spigel, David R
A1 Hamilton, Erika
A1 Bashir, Babar
A1 Gergis, Usama
A1 Murthy, Hemant S
A1 Chumsri, Saranya
A1 Migdady, Yazan
A1 Specht, Jennifer
A1 Chaudhary, Lubna N
A1 Garber, Haven
A1 Kim, Chul
A1 Mamdani, Hirva
A1 Fitzsimmons, Sarah
A1 Ganguly, Bishwa J
A1 Hiraragi, Hajime
A1 Jensen, Helle
A1 Kim, Yeonhee
A1 Lessig, Mary C
A1 Gillenwater, Heidi
YR 2023
UL http://jitc.bmj.com/content/11/Suppl_1/A850.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.